Elvina Almuradova, Associate Professor at Medicana Health Group, shared a post on X:
“FDA approves Zanidatama for HER2+ biliary tract cancer based on HERIZON-BTC-01 trial results:
- ORR: 52%
- DOR: 14.9 months
- First dual HER2-targeted bispecific antibody for BTC
The confirmatory Phase III trial is ongoing.”
Read more about the FDA approval of Zanidatama on oncodaily.com.
More posts featuring Elvina Almuradova.